NAGE Q2 2025 Earnings — Niagen Bioscience Inc Revenue & Financial Results | Market Cap Arena

NAGENiagen Bioscience Inc

$423M

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$31M+36.8% YoY

Gross Profit

$20M65.0% margin

Operating Income

$3M10.2% margin

Net Income

$4M11.6% margin

EPS (Diluted)

$0.04

QoQ Revenue Growth

+2.1%

Cash Flow

Operating Cash Flow

$1M

Free Cash Flow

$1M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$92M

Total Liabilities

$27M

Stockholders' Equity

$64M

Cash & Equivalents

$60M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$31M	$23M	+36.8%
Gross Profit	$20M	$14M	+47.7%
Operating Income	$3M	-$256,000	+1344.1%
Net Income	$4M	-$15,000	+24160.0%